Mar 23, 2020
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Mar 19, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
Mar 16, 2020
Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share
Feb 19, 2020
Hoth Therapeutics Receives Notice of Allowance from European Patent Office
Feb 12, 2020
Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
Feb 11, 2020
Hoth Therapeutics, Inc. to Present at 2020 Noble Capital Market's Sixteenth Annual Small-Cap Investor Conference
Jan 15, 2020
Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects
Dec 19, 2019
Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression
Dec 17, 2019
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board
Dec 09, 2019
Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma
Nov 26, 2019
Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy
Nov 06, 2019
Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment
Oct 15, 2019
Hoth Therapeutics to Present at the Dawson James 5th Annual Small Cap Growth Conference
Oct 14, 2019
Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month"
Oct 08, 2019
Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema
Sep 06, 2019
Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference
Aug 21, 2019
Hoth Therapeutics and Zylö Therapeutics Finalize Agreement
Jun 13, 2019
Hoth Therapeutics to Present to Investors at the Union League of Philadelphia
Jun 06, 2019
Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution
May 14, 2019
Hoth Therapeutics Signs Term Sheet with Zylö Therapeutics to Acquire a License and Jointly Develop a Product to Treat Lupus